SCHEDULE: Millennium Entities Disclose AngioDynamics Stake

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing their passive beneficial ownership of AngioDynamics, Inc. common stock as of December 31, 2025.

Summary

• Integrated Core Strategies (US) LLC beneficially owns 551,565 shares of AngioDynamics, Inc. common stock, representing 1.3% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 842,548 shares of AngioDynamics, Inc. common stock, representing 2.0% of the class.
• The reporting persons hold shared voting power and shared dispositive power over their respective reported shares.
• This filing is an Amendment No. 1 to a Schedule 13G, indicating an update to previously reported ownership.
• The securities are not held for the purpose of changing or influencing control of AngioDynamics, Inc.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of passive ownership and does not contain information that would inherently sway sentiment positively or negatively regarding the issuer's performance or prospects.

Future Outlook

NA

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing reflects routine institutional investment activity in the medical device or healthcare sector, where AngioDynamics operates. Large investment firms like Millennium Management frequently adjust their passive stakes in public companies as part of their portfolio management strategies.

Related Party Transactions

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander are identified as related entities that exercise voting control and investment discretion over the shares held by Integrated Core Strategies (US) LLC.

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership, which can influence market perception and liquidity.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of passive institutional ownership and does not provide new fundamental information about AngioDynamics, Inc. that would warrant a change in investment recommendation. The disclosed stakes are below the 5% threshold for active influence, suggesting a 'hold' recommendation as the filing itself does not present a compelling reason to buy or sell based on new company-specific news.

Keywords

AngioDynamics, ADN, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, beneficial ownership, common stock, institutional ownership